

“Arcutis is building a pioneering company dedicated to revolutionizing treatments for patients with serious diseases of the skin.”

— Frank Watanabe, President and CEO



Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin.

The company’s management team, which includes the industry’s leading topical drug formulator and three dermatologists on staff, has deep experience in dermatology and proven expertise in clinical development, product development, commercialization, finance, and operations. Collectively, the Arcutis executive team has developed or commercialized more than 50 FDA-approved products.

The Opportunity for Dermatology Drug Development

Current standards of care to treat many serious skin diseases are outdated, having remained unchanged for decades, and carry significant treatment limitations, resulting in poor outcomes that can have a negative impact on patient quality of life. Industry consolidation and subsequent disinvestment in R&D by large pharmaceutical players have strangled recent innovation in dermatology drug development. The result is a stagnant innovation pipeline in dermatology with remaining players mostly reformulating older drugs, repackaging them, and charging premium prices, as opposed to identifying novel molecules or mechanisms of action that address dermatologist’s and patients’ problems.

Arcutis was created to fill the innovation void with a focus on elevating the standard of care through innovative therapies that simplify disease management for physicians and eliminate the need to compromise between drug safety, efficacy, and tolerability for patients.

Arcutis Fast Facts

• • •

Founded
2016

Headquarters
Westlake Village, CA

Therapeutic Class
Dermatology

Initial Indications
Psoriasis, atopic dermatitis, and seborrheic dermatitis

Lead Candidate
Topical roflumilast (ARQ-151/154)

Pivotal Trial
Phase 3 trials (DERMIS-1 and -2) for topical roflumilast cream

Market Opportunity* (U.S.)
 Plaque psoriasis: 2.0 million
 Atopic dermatitis: 1.0 million
 Seborrheic dermatitis: 1.7 million
 Scalp psoriasis: 850,000

**Figures represent number of patients treated with topical therapies by dermatologists*

Arcutis is rapidly advancing a robust pipeline including four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The pipeline includes best-in-class molecules that are the products of scientific advances in the understanding of key immunology targets such as phosphodiesterase-4 (PDE4) and Janus kinase type 1 (JAK1) and their role in the inflammation that drives many dermatological conditions.

Management Team

• • •

General Counsel

• • •

805-418-5006, Ext. 740

		Preclinical	Phase 1	Phase 2	Phase 3
Topical Roflumilast Cream (ARQ-151) Cream (PDE4i)	Plaque Psoriasis	● ● ● ● ● ●	● ● ● ● ● ● ●	● ● ● ● ● ● ●	● ● ●
	Atopic Dermatitis	● ● ● ● ● ●	● ● ● ● ● ● ●	● ● ●	
Topical Roflumilast Foam (ARQ-154) Foam (PDE4i)	Seborrheic Dermatitis	● ● ● ● ● ●	● ● ● ● ● ● ●	● ● ●	
	Scalp Psoriasis	● ● ● ● ● ●	● ● ● ● ● ● ●	● ● ●	
ARQ-252 (JAK1i)	Hand Eczema	● ● ● ● ● ●	● ● ● ● ● ● ●	● ● ●	
	Vitiligo	● ● ● ● ● ●	● ● ● ● ● ● ●		
ARQ-255 (JAK1i)	Alopecia Areata	● ● ● ●			

